Details of the Drug

General Information of Drug (ID: DM0DTF7)

Drug Name
Zonisamide
Synonyms
Exceglan; Excegram; Excegran; Tremode; Trerief; Zonegran; Zonisamida; Zonisamidum; Elan brand of zonisamide; Zonisamida [Spanish]; Zonisamide monosodium; Zonisamidum [Latin]; AD 810; PD 110843; SPR_2; AD-810; AD-810N; E-2090; Excegran (TN); PD-110843; Zonegran (TN); Zonegran, Zonisamide; Zonisamide (ZNS); Zonisamide (JAN/USAN/INN); Zonisamide [USAN:BAN:INN:JAN]; 1,2-Benzisoxazole-3-methanesulfonamide; 1,2-benzoxazol-3-ylmethanesulfonamide; 1-(1,2-Benzoxazol-3-Yl)methanesulfonamide; 1-(1,2-benzisoxazol-3-yl)methanesulfonamide; 3-(Sulfamoylmethyl)-1,2-benzisoxazole; 3-sulfamoylmethyl-1,2-benzisoxazole
Indication
Disease Entry ICD 11 Status REF
Epilepsy 8A60-8A68 Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 212.23
Topological Polar Surface Area (xlogp) 0.2
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability
99% of drug becomes completely available to its intended biological destination(s) [4]
Elimination
22% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 63 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 40.3875 micromolar/kg/day [7]
Vd
The volume of distribution (Vd) of drug is 1.45 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 0.8 mg/mL [3]
Chemical Identifiers
Formula
C8H8N2O3S
IUPAC Name
1,2-benzoxazol-3-ylmethanesulfonamide
Canonical SMILES
C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N
InChI
InChI=1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
InChIKey
UBQNRHZMVUUOMG-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5734
CAS Number
68291-97-4
DrugBank ID
DB00909
TTD ID
D09ZIS
INTEDE ID
DR1737
ACDINA ID
D00745

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Sodium channel unspecific (NaC) TTRK8B9 NOUNIPROTAC Blocker [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [11]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [13]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [14]
Aldehyde oxidase (AOX) DE8UGTM A0A1V9IQJ2_CLOSG Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Zonisamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cenobamate DMGOVHA Moderate Increased metabolism of Zonisamide caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Stiripentol DMMSDOY Moderate Decreased metabolism of Zonisamide caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Zonisamide caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Phenobarbital DMXZOCG Moderate Increased metabolism of Zonisamide caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [67]
Coadministration of a Drug Treating the Disease Different from Zonisamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Zonisamide caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [67]
Arn-509 DMT81LZ Moderate Increased metabolism of Zonisamide caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [67]
Mepyramine DMB4SFH Major Increased risk of hyperpyrexia by the combination of Zonisamide and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [68]
Phenyltoloxamine DMKAEQW Major Additive CNS depression effects by the combination of Zonisamide and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [68]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Zonisamide caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [67]
Nifedipine DMSVOZT Moderate Decreased metabolism of Zonisamide caused by Nifedipine mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [67]
Posaconazole DMUL5EW Moderate Decreased metabolism of Zonisamide caused by Posaconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [67]
Desipramine DMT2FDC Major Increased risk of hyperpyrexia by the combination of Zonisamide and Desipramine. Attention deficit hyperactivity disorder [6A05] [68]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Zonisamide caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Zonisamide caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Troleandomycin DMUZNIG Moderate Decreased metabolism of Zonisamide caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [67]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Zonisamide caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [69]
Cariprazine DMJYDVK Major Increased risk of hyperpyrexia by the combination of Zonisamide and Cariprazine. Bipolar disorder [6A60] [68]
Pexidartinib DMS2J0Z Moderate Increased metabolism of Zonisamide caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [67]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Zonisamide caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [70]
Tucatinib DMBESUA Moderate Decreased metabolism of Zonisamide caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [67]
Levomilnacipran DMV26S8 Moderate Antagonize the effect of Zonisamide when combined with Levomilnacipran. Chronic pain [MG30] [71]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Zonisamide caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [67]
MK-8228 DMOB58Q Moderate Decreased metabolism of Zonisamide caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [67]
Sertraline DM0FB1J Moderate Antagonize the effect of Zonisamide when combined with Sertraline. Depression [6A70-6A7Z] [71]
Cyclobenzaprine DM1YBRM Major Increased risk of hyperpyrexia by the combination of Zonisamide and Cyclobenzaprine. Depression [6A70-6A7Z] [68]
Vilazodone DM4LECQ Moderate Antagonize the effect of Zonisamide when combined with Vilazodone. Depression [6A70-6A7Z] [71]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Zonisamide caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [67]
Vortioxetine DM6F1PU Moderate Antagonize the effect of Zonisamide when combined with Vortioxetine. Depression [6A70-6A7Z] [71]
Milnacipran DMBFE74 Moderate Antagonize the effect of Zonisamide when combined with Milnacipran. Depression [6A70-6A7Z] [71]
Escitalopram DMFK9HG Moderate Antagonize the effect of Zonisamide when combined with Escitalopram. Depression [6A70-6A7Z] [71]
Desvenlafaxine DMHD4PE Moderate Antagonize the effect of Zonisamide when combined with Desvenlafaxine. Depression [6A70-6A7Z] [71]
OPC-34712 DMHG57U Major Increased risk of hyperpyrexia by the combination of Zonisamide and OPC-34712. Depression [6A70-6A7Z] [68]
Clomipramine DMINRKW Major Increased risk of hyperpyrexia by the combination of Zonisamide and Clomipramine. Depression [6A70-6A7Z] [68]
Doxepin DMPI98T Major Increased risk of hyperpyrexia by the combination of Zonisamide and Doxepin. Depression [6A70-6A7Z] [68]
Maprotiline DMPWB7T Major Increased risk of hyperpyrexia by the combination of Zonisamide and Maprotiline. Depression [6A70-6A7Z] [68]
Esketamine DMVU687 Moderate Additive CNS depression effects by the combination of Zonisamide and Esketamine. Depression [6A70-6A7Z] [72]
Mepenzolate DM8YU2F Major Additive CNS depression effects by the combination of Zonisamide and Mepenzolate. Digestive system disease [DE2Z] [68]
Oxybutynine DMJPBAX Major Increased risk of hyperpyrexia by the combination of Zonisamide and Oxybutynine. Discovery agent [N.A.] [68]
Diphenhydramine DMKQTBA Major Increased risk of hyperpyrexia by the combination of Zonisamide and Diphenhydramine. Episodic vestibular syndrome [AB31] [68]
Tazemetostat DMWP1BH Moderate Increased metabolism of Zonisamide caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [67]
Solifenacin DMG592Q Major Increased risk of hyperpyrexia by the combination of Zonisamide and Solifenacin. Functional bladder disorder [GC50] [68]
Tolterodine DMSHPW8 Major Increased risk of hyperpyrexia by the combination of Zonisamide and Tolterodine. Functional bladder disorder [GC50] [68]
Itraconazole DMCR1MV Moderate Decreased metabolism of Zonisamide caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [67]
Miconazole DMPMYE8 Moderate Decreased metabolism of Zonisamide caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [67]
Ketoconazole DMPZI3Q Moderate Decreased metabolism of Zonisamide caused by Ketoconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [67]
Sulfinpyrazone DMEV954 Moderate Increased metabolism of Zonisamide caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [67]
Boceprevir DMBSHMF Moderate Decreased metabolism of Zonisamide caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [67]
Telaprevir DMMRV29 Moderate Decreased metabolism of Zonisamide caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [67]
Rifampin DMA8J1G Moderate Increased metabolism of Zonisamide caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [67]
Rifapentine DMCHV4I Moderate Increased metabolism of Zonisamide caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [67]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Zonisamide caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Etravirine DMGV8QU Moderate Increased metabolism of Zonisamide caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Belladonna DM2RBWK Major Increased risk of hyperpyrexia by the combination of Zonisamide and Belladonna. Infectious gastroenteritis/colitis [1A40] [68]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Zonisamide caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [67]
Amobarbital DM0GQ8N Moderate Increased metabolism of Zonisamide caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [67]
ITI-007 DMUQ1DO Major Increased risk of hyperpyrexia by the combination of Zonisamide and ITI-007. Insomnia [7A00-7A0Z] [68]
Crizotinib DM4F29C Moderate Decreased metabolism of Zonisamide caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Brigatinib DM7W94S Moderate Increased metabolism of Zonisamide caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [74]
Ceritinib DMB920Z Moderate Decreased metabolism of Zonisamide caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
PF-06463922 DMKM7EW Moderate Increased metabolism of Zonisamide caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [67]
Selpercatinib DMZR15V Moderate Decreased metabolism of Zonisamide caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [67]
Hydroxychloroquine DMSIVND Moderate Antagonize the effect of Zonisamide when combined with Hydroxychloroquine. Malaria [1F40-1F45] [72]
Idelalisib DM602WT Moderate Decreased metabolism of Zonisamide caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [67]
IPI-145 DMWA24P Moderate Decreased metabolism of Zonisamide caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [67]
Vemurafenib DM62UG5 Moderate Increased metabolism of Zonisamide caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [67]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Zonisamide caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [67]
Danazol DML8KTN Moderate Decreased metabolism of Zonisamide caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [67]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Zonisamide and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [75]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Zonisamide and Lasmiditan. Migraine [8A80] [76]
Exjade DMHPRWG Moderate Decreased metabolism of Zonisamide caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [77]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Zonisamide and Flibanserin. Mood disorder [6A60-6E23] [78]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Zonisamide and Thalidomide. Multiple myeloma [2A83] [79]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Zonisamide caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [67]
Nilotinib DM7HXWT Moderate Decreased metabolism of Zonisamide caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [80]
Dasatinib DMJV2EK Moderate Decreased metabolism of Zonisamide caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [81]
Phenindamine DMDTC7R Major Additive CNS depression effects by the combination of Zonisamide and Phenindamine. Nasopharyngitis [CA00] [68]
Dimenhydrinate DM264B3 Major Increased risk of hyperpyrexia by the combination of Zonisamide and Dimenhydrinate. Nausea/vomiting [MD90] [68]
Promethazine DM6I5GR Major Increased risk of hyperpyrexia by the combination of Zonisamide and Promethazine. Nausea/vomiting [MD90] [68]
Cyclizine DM9G7BS Major Increased risk of hyperpyrexia by the combination of Zonisamide and Cyclizine. Nausea/vomiting [MD90] [68]
Netupitant DMEKAYI Moderate Decreased metabolism of Zonisamide caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [67]
Entrectinib DMMPTLH Moderate Decreased metabolism of Zonisamide caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [67]
Levomethadyl Acetate DM06HG5 Major Additive CNS depression effects by the combination of Zonisamide and Levomethadyl Acetate. Opioid use disorder [6C43] [78]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Zonisamide and Apraclonidine. Optic nerve disorder [9C40] [82]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Zonisamide caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [67]
Flavoxate DMKV4NL Major Increased risk of hyperpyrexia by the combination of Zonisamide and Flavoxate. Pain [MG30-MG3Z] [68]
Buprenorphine DMPRI8G Major Additive CNS depression effects by the combination of Zonisamide and Buprenorphine. Pain [MG30-MG3Z] [83]
Orphenadrine DMW542E Major Increased risk of hyperpyrexia by the combination of Zonisamide and Orphenadrine. Parkinsonism [8A00] [68]
Abametapir DM2RX0I Moderate Decreased metabolism of Zonisamide caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [84]
Methylscopolamine DM5VWOB Major Additive CNS depression effects by the combination of Zonisamide and Methylscopolamine. Peptic ulcer [DA61] [68]
Lefamulin DME6G97 Moderate Decreased metabolism of Zonisamide caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [85]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Zonisamide caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [67]
Enzalutamide DMGL19D Moderate Increased metabolism of Zonisamide caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [67]
Levomepromazine DMIKFEL Major Increased risk of hyperpyrexia by the combination of Zonisamide and Levomepromazine. Psychotic disorder [6A20-6A25] [68]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Zonisamide and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [86]
Dexamethasone DMMWZET Moderate Increased metabolism of Zonisamide caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [67]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Zonisamide and Quetiapine. Schizophrenia [6A20] [68]
Mesoridazine DM2ZGAN Major Increased risk of hyperpyrexia by the combination of Zonisamide and Mesoridazine. Schizophrenia [6A20] [68]
Aripiprazole DM3NUMH Major Increased risk of hyperpyrexia by the combination of Zonisamide and Aripiprazole. Schizophrenia [6A20] [68]
Iloperidone DM6AUFY Major Increased risk of hyperpyrexia by the combination of Zonisamide and Iloperidone. Schizophrenia [6A20] [68]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Zonisamide and Paliperidone. Schizophrenia [6A20] [68]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Zonisamide and Molindone. Schizophrenia [6A20] [68]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Zonisamide and Thiothixene. Schizophrenia [6A20] [68]
Asenapine DMSQZE2 Major Increased risk of hyperpyrexia by the combination of Zonisamide and Asenapine. Schizophrenia [6A20] [68]
Pimozide DMW83TP Major Increased risk of hyperpyrexia by the combination of Zonisamide and Pimozide. Schizophrenia [6A20] [68]
Voxelotor DMCS6M5 Moderate Decreased metabolism of Zonisamide caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [67]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Zonisamide caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [87]
Larotrectinib DM26CQR Moderate Decreased metabolism of Zonisamide caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [67]
Armodafinil DMGB035 Minor Increased metabolism of Zonisamide caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
LEE011 DMMX75K Moderate Decreased metabolism of Zonisamide caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [67]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Zonisamide caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [89]
Chlorpheniramine DM5URA2 Major Increased risk of hyperpyrexia by the combination of Zonisamide and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [68]
Trimeprazine DMEMV9D Major Increased risk of hyperpyrexia by the combination of Zonisamide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [68]
Acrivastine DMTIGA0 Major Additive CNS depression effects by the combination of Zonisamide and Acrivastine. Vasomotor/allergic rhinitis [CA08] [68]
⏷ Show the Full List of 109 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
FD&C red no. 4 E00356 62542 Colorant
Hydrazine yellow E00409 164825 Colorant
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Eisenoxyd E00585 56841934 Colorant
FD&C red no. 3 E00629 Not Available Colorant
Ferrosoferric oxide E00231 14789 Colorant
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Water E00035 962 Solvent
⏷ Show the Full List of 24 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Zonisamide 100 mg capsule 100 mg Oral Capsule Oral
Zonisamide 25 mg capsule 25 mg Oral Capsule Oral
Zonisamide 50 mg capsule 50 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7047).
2 Use of second-generation antiepileptic drugs in the pediatric population. Paediatr Drugs. 2008;10(4):217-54.
3 BDDCS applied to over 900 drugs
4 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Antiepileptic drugs and relapse after epilepsy surgery. Epileptic Disord. 2008 Sep;10(3):193-8.
10 Pharmacokinetics and drug interactions with zonisamide. Epilepsia. 2007 Mar;48(3):435-41.
11 Actual and Predicted Pharmacokinetic Interactions Between Anticonvulsants and Antiretrovirals.
12 Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004 Nov;62(1):1-11.
13 Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data. Eur J Clin Pharmacol. 1998 Apr;54(2):177-83.
14 Differential catalytic properties in metabolism of endogenous and exogenous substrates among CYP3A enzymes expressed in COS-7 cells. Biochim Biophys Acta. 1998 May 8;1380(3):297-304.
15 The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997 Mar;49(3):253-6.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
26 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
27 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
28 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
29 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
30 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
31 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
32 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
33 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
34 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
35 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
36 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
37 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
38 Drug Interactions Flockhart Table
39 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
40 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
41 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
42 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
43 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
44 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
45 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
46 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
47 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
48 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
49 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
50 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
51 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
52 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
53 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
54 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
55 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
56 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
57 Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders. CNS Drugs. 2009;23(7):555-68.
58 Sidedness of carbamazepine accessibility to voltage-gated sodium channels. Mol Pharmacol. 2014 Feb;85(2):381-7.
59 Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX). Epilepsy Res. 2009 Jan;83(1):1-43.
60 Synthesis and pharmacological evaluation of phenylacetamides as sodium-channel blockers. J Med Chem. 1994 Jan 21;37(2):268-74.
61 Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem. 2001 Jan 18;44(2):115-37.
62 Block of neuronal tetrodotoxin-resistant Na+ currents by stereoisomers of piperidine local anesthetics. Anesth Analg. 2000 Dec;91(6):1499-505.
63 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
64 In vitro assays for repellents and deterrents for ticks: differing effects of products when tested with attractant or arrestment stimuli. Med Vet Entomol. 2003 Dec;17(4):370-8.
65 Emerging drugs for epilepsy. Expert Opin Emerg Drugs. 2007 Sep;12(3):407-22.
66 WO patent application no. 2008,0857,11, Synergy of sodium channel blockers and calcium channel blockers.
67 Nakasa H, Nakamura H, Ono S, Tsutsui M, Kiuchi M, Ohmori S, Kitada M "Prediction of drug-drug interactions of zonisamide metabolism in humans from in vitro data." Eur J Clin Pharmacol 54 (1998): 177-83. [PMID: 9626925]
68 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
69 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
70 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
71 Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
72 Cerner Multum, Inc. "Australian Product Information.".
73 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
74 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
75 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
76 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
77 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
78 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
79 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
80 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
81 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
82 Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
83 Sekar M, Mimpriss TJ "Buprenorphine, benzodiazepines and prolonged respiratory depression." Anaesthesia 42 (1987): 567-8. [PMID: 3592200]
84 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
85 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
86 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
87 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
88 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
89 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.